This site is intended for health professionals only

At the heart of general practice since 1960

Pneumococcal jab in elderly queried

A new vaccine against streptococcal A infection is well tolerated and capable of stimulating an immune response, according to an early trial.

Work on streptococcal A vaccines was halted in the 1970s because of safety fears but is now a priority after increasing problems with antibiotic resistance.

In the new phase I trial, published in JAMA (August 11), healthy volunteers were given a vaccine made from several proteins from the streptococcus A bacterium. They produced immune responses that are likely to confer protection against a range of subtypes of streptococcal A infection.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say